At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
RZL-012 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas
In Brief
A Phase 2 clinical trial evaluating RZL-012 and Vehicle for Dercum's Disease Lipomas. Completed, enrolled 38 participants across 1 site.
Detailed Summary
Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDercum's Disease Lipomas
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartJul 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedJan 14, 2020
Enrollment StartJul 30, 2020
Primary CompletionFeb 20, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.5 years ago
Interventions
RZL-012drug
small synthetic molecule for the treatment of Dercum's Disease lipomas
Vehicledrug
Vehicle of RZL-012 drug product